Terpene Control in Scaleable Cannabinoids Medicinal Formulations
US-2024390319-A1 · Nov 28, 2024 · US
Method of treating dry eye syndrome using pharmaceutical composition having extract of Terminalia chebula or fraction thereof
US11058736B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11058736-B2 |
| Application number | US-201916549767-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 23, 2019 |
| Priority date | Aug 24, 2018 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are a pharmaceutical composition for preventing or treating dry eye syndrome, including an extract of Terminalia chebula or a fraction thereof as an active ingredient, and a method of preventing or treating dry eye syndrome in an individual.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating dry eye syndrome in an individual, the method comprising: administering a pharmaceutical composition to the individual in an amount effective to treat dry eye syndrome, wherein the pharmaceutical composition comprises an extract of Terminalia chebula or a fraction thereof as an active ingredient for increasing an amount of tear secretion, wherein the extract is obtained using a C1-C6 alcohol, or a mixture of the C1-C6 alcohol, as a solvent, wherein the composition comprises the extract of Terminalia chebula or a fraction thereof as a single active ingredient, and wherein the composition is formulated for oral administration. 2. The method of treating dry eye syndrome in an individual according to claim 1 , wherein the alcohol is methanol, ethanol, propanol, butanol, pentanol, or hexanol. 3. The method of treating dry eye syndrome in an individual according to claim 1 , wherein the fraction is a hexane fraction, an ethyl acetate fraction, a butanol fraction, or a water fraction of the extract of Terminalia chebula. 4. The method of treating dry eye syndrome in an individual according to claim 1 , wherein the composition increases an amount of tear secretion or inhibits morphological change in a cornea.
Assignees
Inventors
Classifications
- A61K36/185Primary
Magnoliopsida (dicotyledons) · CPC title
using mixed solvents, e.g. 70% EtOH · CPC title
- A61P27/04Primary
Artificial tears; Irrigation solutions · CPC title
Eye, e.g. artificial tears · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11058736B2 cover?
- Provided are a pharmaceutical composition for preventing or treating dry eye syndrome, including an extract of Terminalia chebula or a fraction thereof as an active ingredient, and a method of preventing or treating dry eye syndrome in an individual.
- Who is the assignee on this patent?
- Korea Inst Sci & Tech
- What technology area does this patent fall under?
- Primary CPC classification A61K36/185. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).